ONL Therapeutics Receives Orphan Drug Designation for ONL1204 for Treatment of Retinal Detachment from FDA
ANN ARBOR, MI – February 11, 2016 – ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced [...]
ONL Therapeutics to Present at the 2015 Ophthalmology Innovation Summit at the American Academy of Ophthalmology Annual Meeting
ANN ARBOR, MI – October 29, 2015 – ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced [...]
ONL Therapeutics Announces Formation of Scientific Advisory Board
Renowned Retinal Disease Thought Leaders to Help Guide Development of Novel Vision Protection Technology in Age-Related Macular Degeneration (AMD) and Retinal Detachment ANN ARBOR, MI – [...]